sorafenib has been researched along with 2,4-thiazolidinedione in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (2,4-thiazolidinedione) | Trials (2,4-thiazolidinedione) | Recent Studies (post-2010) (2,4-thiazolidinedione) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 798 | 33 | 294 |
| Protein | Taxonomy | sorafenib (IC50) | 2,4-thiazolidinedione (IC50) |
|---|---|---|---|
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | 0.54 | |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | 0.54 | |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | 0.54 | |
| Probable maltase-glucoamylase 2 | Homo sapiens (human) | 0.54 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abulkhair, HS; El-Adl, K; El-Hddad, SSA; El-Helby, AA; Nasser, M; Sakr, H | 1 |
1 other study(ies) available for sorafenib and 2,4-thiazolidinedione
| Article | Year |
|---|---|
Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Design; HCT116 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Thiazolidinediones; Vascular Endothelial Growth Factor Receptor-2 | 2021 |